tablets Diroton are applied at the following indications:

• arterial hypertension;
• heart failure (symptomatic treatment);
• an acute myocardial infarction (short-term treatment within 6 weeks of hemodynamically stable patients not later than in 24 hours after an acute myocardial infarction);
• treatment of diseases of kidneys at patients with arterial hypertension, patients with diabetes of the II type and an initial nephropathy.

Structure

Active ingredient: lisinopril;

1 tablet contains 5 mg or 10 mg or 20 mg of lisinopril in the form of dihydrate lisinopril;

Excipients: magnesium stearate talc attracts (E 421) starch corn hydrophosphate of calcium a dihydrate.

Contraindication

• hypersensitivity to acting or to excipient of drug;
• hypersensitivity to the APF any other inhibitor;
• Quincke's disease in the anamnesis connected with the previous treatment by other APF inhibitors;
• hereditary or idiopathic Quincke's disease;
• pregnant women or women who are going to become pregnant;
• feeding period breast;
• simultaneous use of the medicament Diroton with the medicaments containing aliskiren to patients with diabetes or a renal failure (glomerular filtration rate <60 ml/minute / 1.73 m ² ).

Route of administration

Dosage has to be individual according to a disease of the patient and reaction of arterial blood pressure. Accept in 1 times a day, daily at the same time, irrespective of meal.

Pregnant

Medicine it is contraindicated to the pregnant women or women planning pregnancy to apply

Feature of use

As information on a possibility of use of lisinopril during feeding by a breast is absent, intake of lisinopril during this period is contraindicated.

Children

At children with arterial hypertension aged> 6 years, means has limited efficiency and safety, however there are no data on other indications. Lisinopril is not recommended to be applied to treatment of children according to other indications except arterial hypertension. Lisinopril is not recommended to be applied to treatment of children aged up to 6 years or children with a heavy renal failure (SKF <30 ml/minute / 1.73м ² ).

Drivers

Considering possibility of dizziness and development of fatigue, lisinopril can affect ability to run motor transport and other mechanisms, especially in an initiation of treatment. Therefore it is necessary to refrain from control of motor transport and work with other mechanisms before establishment of individual reaction to drug.

Data on overdose of the medicament Diroton at people are limited to

. The symptoms connected with overdose of APF inhibitors can include arterial hypotension, circulator shock, disturbance of electrolytic balance, a renal failure, a hyperventilation, tachycardia, a cardiopalmus, bradycardia, dizziness, concern and cough.

to

At overdose recommends administration of normal saline solution. In cases of developing of arterial hypotension of the patient it is necessary to put in horizontal position. If there is an opportunity, it is possible to apply infusional administration of angiotensin II and/or intravenous administration of catecholamines. If medicament was used recently, it is necessary to take measures for a lisinopril conclusion from an organism (for example, to cause vomiting, to wash out a stomach, to accept absorbents and sodium sulfate). Lisinopril can be removed from the general blood-groove by means of a hemodialysis. It is necessary to check often indicators of vitals, concentration of electrolytes and creatinine in blood serum. Use of a pacemaker is shown in bradycardia, resistant to therapy.

Side effects

from nervous system: frequent (from ≥ 1/100 to <1/10) - dizziness, a headache.

Vascular disorders: frequent (from ≥ 1/100 to <1/10) - orthostatic disturbances (including hypotension).

from the respiratory system, bodies of a thorax and mediastinum: frequent (from ≥ 1/100 to <1/10) - cough.

from a digestive tract: frequent (from ≥ 1/100 to <1/10) - diarrhea, vomiting.

from kidneys and an urinary system: frequent (from ≥ 1/100 to <1/10) - a renal failure.

Concomitant use of antidiabetic means (insulin, oral hypoglycemic drugs) with APF inhibitors can lead

to strengthening of effect of decrease in glucose in blood with risk of development of a hypoglycemia. This phenomenon, as a rule, will be shown more likely in the first week of the combined treatment and at patients with a renal failure.

Storage conditions

to Store

at a temperature not above 30 °C, out of children's reach.

Expiration date - 3 years.